Prednisone
Rayos (prednisone) is a small molecule pharmaceutical. Prednisone was first approved as Paracort on 1982-01-01. It is used to treat adrenal insufficiency, allergic conjunctivitis, allergic rhinitis, ankylosing spondylitis, and asthma amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Top Prescription Drugs
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| musculoskeletal diseases | D009140 |
| digestive system diseases | D004066 |
| respiratory tract diseases | D012140 |
| otorhinolaryngologic diseases | D010038 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| urogenital diseases | D000091642 |
| hemic and lymphatic diseases | D006425 |
Show 8 more
Trade Name
FDA
EMA
Rayos (generic drugs available since 1982-01-01, discontinued: Cortan, Deltasone, Deltome, Fernisone, Liquid pred, Meticorten, Orasone, Paracort, Prednicen, Servisone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prednisone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAYOS | Horizon Pharmaceutical | N-202020 RX | 2012-07-26 | 3 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cortane-b | unapproved drug other | 2017-03-20 |
| deltasone | ANDA | 2018-11-02 |
| prednisone | ANDA | 2023-06-01 |
| rayos | New Drug Application | 2020-09-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| adrenal insufficiency | — | D000309 | — |
| allergic conjunctivitis | EFO_0007141 | D003233 | H10.44 |
| allergic rhinitis | — | D065631 | J30.9 |
| ankylosing spondylitis | EFO_0003898 | D013167 | M45 |
| asthma | EFO_0000270 | D001249 | J45 |
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
| berylliosis | EFO_0007168 | D001607 | J63.2 |
| bursitis | EFO_1000941 | D002062 | M71.9 |
| collagen diseases | — | D003095 | — |
| contact dermatitis | — | D003877 | L25 |
Show 23 more
Agency Specific
FDA
EMA
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EA: Corticosteroids acting locally
— A07EA03: Prednisone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB07: Prednisone
HCPCS
Code | Description |
|---|---|
| G2112 | Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months |
| G2113 | Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity |
| G9468 | Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills |
| G9470 | Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg |
Clinical
Clinical Trials
1326 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 47 | 140 | 52 | 5 | 5 | 221 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 29 | 46 | 20 | 1 | 2 | 81 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 14 | 33 | 18 | 7 | 6 | 71 | |
| Castration-resistant prostatic neoplasms | D064129 | 16 | 28 | 10 | 2 | 2 | 48 | ||
| Multiple myeloma | D009101 | C90.0 | 10 | 25 | 18 | 2 | 2 | 47 | |
| Asthma | D001249 | EFO_0000270 | J45 | 4 | 2 | 9 | 5 | 5 | 25 |
| Follicular lymphoma | D008224 | C82 | 9 | 11 | 6 | 1 | 1 | 21 | |
| Kidney transplantation | D016030 | 2 | 6 | 2 | 12 | — | 21 | ||
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 6 | 3 | 6 | 5 | 20 |
| Graft vs host disease | D006086 | D89.81 | 2 | 6 | 6 | 1 | 3 | 17 |
Show 90 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 20 | 80 | 38 | — | 8 | 134 | |
| Leukemia | D007938 | C95 | 6 | 24 | 15 | — | 3 | 45 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 14 | 22 | 8 | — | 2 | 38 | |
| Hodgkin disease | D006689 | C81 | 3 | 16 | 11 | — | 1 | 27 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | 6 | 12 | 4 | — | — | 21 | |
| B-cell lymphoma | D016393 | 10 | 9 | 3 | — | — | 19 | ||
| Adenocarcinoma | D000230 | 1 | 16 | 1 | — | — | 18 | ||
| Neoplasms | D009369 | C80 | 10 | 6 | 2 | — | — | 16 | |
| Plasma cell neoplasms | D054219 | 4 | 6 | 5 | — | — | 14 | ||
| Lupus nephritis | D008181 | EFO_0005761 | — | 7 | 8 | — | — | 14 |
Show 58 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burkitt lymphoma | D002051 | C83.7 | 9 | 6 | — | — | — | 12 | |
| Myelodysplastic syndromes | D009190 | D46 | 4 | 7 | — | — | — | 10 | |
| Myeloproliferative disorders | D009196 | D47.1 | 2 | 3 | — | — | — | 5 | |
| Plasmablastic lymphoma | D000069293 | C83.3 | 4 | 2 | — | — | — | 4 | |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | 4 | 1 | — | — | — | 4 | ||
| Melanoma | D008545 | 1 | 3 | — | — | — | 4 | ||
| Inflammation | D007249 | 1 | 2 | — | — | 2 | 4 | ||
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | 2 | 2 | — | — | — | 3 | |
| Biphenotypic leukemia acute | D015456 | C95.0 | 1 | 2 | — | — | — | 3 | |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 2 | — | — | 1 | 3 |
Show 91 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | — | — | 9 | ||
| T-cell leukemia | D015458 | 2 | — | — | — | — | 2 | ||
| Syndrome | D013577 | 1 | — | — | — | 1 | 2 | ||
| Drug hypersensitivity syndrome | D063926 | EFO_1002004 | D72.12 | 1 | — | — | — | 1 | 2 |
| Squamous cell carcinoma | D002294 | 1 | — | — | — | — | 1 | ||
| Urologic neoplasms | D014571 | C64-C68 | 1 | — | — | — | — | 1 | |
| Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 | ||
| Ovarian epithelial carcinoma | D000077216 | 1 | — | — | — | — | 1 | ||
| Basal cell carcinoma | D002280 | 1 | — | — | — | — | 1 | ||
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 1 | — | — | — | — | 1 |
Show 16 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | 3 | 3 | ||
| Allergic bronchopulmonary aspergillosis | D001229 | EFO_0007140 | B44.81 | — | — | — | — | 2 | 2 |
| Undifferentiated connective tissue diseases | D000074079 | — | — | — | — | 1 | 1 | ||
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Wiskott-aldrich syndrome | D014923 | D82.0 | — | — | — | — | 1 | 1 | |
| Severe combined immunodeficiency | D016511 | D81.0 | — | — | — | — | 1 | 1 | |
| Hemophagocytic lymphohistiocytosis | D051359 | D76.1 | — | — | — | — | 1 | 1 | |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | — | — | 1 | 1 |
| Type 1 hyper-igm immunodeficiency syndrome | D053307 | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PREDNISONE |
| INN | prednisone |
| Description | Prednisone is a synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. It has a role as a prodrug, an anti-inflammatory drug, an antineoplastic agent, an immunosuppressive agent and an adrenergic agent. It is a 20-oxo steroid, an 11-oxo steroid, a 21-hydroxy steroid, a 17alpha-hydroxy steroid, a glucocorticoid, a 3-oxo-Delta(1),Delta(4)-steroid, a primary alpha-hydroxy ketone, a tertiary alpha-hydroxy ketone and a C21-steroid. |
| Classification | Small molecule |
| Drug class | prednisone and prednisolone derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO |
Identifiers
| PDB | — |
| CAS-ID | 53-03-2 |
| RxCUI | 8640 |
| ChEMBL ID | CHEMBL635 |
| ChEBI ID | 8382 |
| PubChem CID | 5865 |
| DrugBank | DB00635 |
| UNII ID | VB0R961HZT (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Rayos - Horizon Therapeutics Public
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 96,253 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
125,600 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more